Novartis to file for new Lucentis® (ranibizumab) indication in retinopathy of prematurity
Novartis announced results from a Phase III study of Lucentis® (ranibizumab) versus laser surgery (current standard of care) in premature infants with retinopathy of prematurity. Lucentis pharmacologically targets and reduces the elevated intraocular level of VEGF. September 22, 2018